How far do you go with your outsourcing? This question has by now faced all companies that strive to meet development deadlines by producing material and data needed to advance molecules in the clinic. The need to do so in a compliant and cost-effective way has increased dramatically in the last 10 years as regulatory expectations evolve and R&D budgets are under significant downward pressure. For evolving or virtual biotech firms the financial questions come easiest, as the funding to buil...